Clinical Scorecard: Lysosomal Acid Lipase Deficiency Leading to Hepatic Steatosis
At a Glance
Category
Detail
Condition
Lysosomal Acid Lipase Deficiency (LAL-D), a rare autosomal-recessive lysosomal storage disease causing microvesicular hepatic steatosis and fibrosis
Key Mechanisms
Complete or partial deficiency of lysosomal acid lipase leads to cholesterol ester and triglyceride accumulation in hepatocytes, activating de novo lipogenesis via SREBP1c and reducing HDL production via LXR pathways
Target Population
Children and adults with unexplained microvesicular hepatic steatosis, dyslipidemia, and progressive liver disease
Care Setting
Hepatology outpatient clinics and specialized metabolic or genetic centers
Key Highlights
LAL-D presents with microvesicular steatosis, fibrosis, and orange-colored liver due to cholesterol deposition
Laboratory findings include elevated LDL, total cholesterol, triglycerides, mildly elevated ALT, and low HDL
Enzyme replacement therapy with sebelipase alfa is available and can be life-saving if diagnosed timely
Guideline-Based Recommendations
Diagnosis
Consider LAL-D in patients with unexplained microvesicular steatosis and dyslipidemia
Confirm diagnosis by measuring lysosomal acid lipase activity in blood or tissue
Genetic testing for mutations such as homozygous E8SJM (c.894G>A) mutation can confirm diagnosis
Management
Initiate enzyme replacement therapy with sebelipase alfa to reduce lipid accumulation and prevent progression
Manage dyslipidemia and monitor liver function regularly
Avoid hepatotoxic substances including alcohol and unnecessary medications
Monitoring & Follow-up
Regular assessment of liver enzymes, lipid profile, and fibrosis progression
Surveillance for complications including cirrhosis, hepatocellular carcinoma, and cardiovascular events
Monitor treatment response to enzyme replacement therapy
Risks
Progression to end-stage liver disease, cirrhosis, and hepatocellular carcinoma
High risk of premature atherosclerosis leading to cerebral or myocardial infarction
Potential lethality in infancy in complete LAL deficiency (Wolman disease)
Patient & Prescribing Data
Patients with confirmed LAL-D exhibiting microvesicular steatosis and dyslipidemia
Sebelipase alfa enzyme replacement therapy can halt or reverse disease progression and improve lipid abnormalities
Clinical Best Practices
Maintain high suspicion for LAL-D in young patients with unexplained microvesicular steatosis and dyslipidemia
Perform liver biopsy and enzyme activity testing early to confirm diagnosis
Initiate enzyme replacement therapy promptly upon diagnosis
Educate patients about disease progression risks and importance of adherence to therapy
Coordinate multidisciplinary care including hepatology, genetics, and cardiology
